AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22171732 — intervention group
Group type: COMPARATOR
Intervention: Control program (computer-based)
Number of subjects: 200
Study 20354760 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 18552688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxalated hemoglobin polyoxyethylene (PHP) at 0.25 mL/kg/hr (20 mg/kg/hr)
Number of subjects: 62
Study 18552688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxalated hemoglobin polyoxyethylene (PHP)
Number of subjects: 62
Study 18552688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 15780531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - continuous combined 0.625 mg conjugated equine estrogen plus 2.5 mg/d medoxyprogesterone
Number of subjects: 16
Study 15780531 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (T)
Number of subjects: 16
Study 15780531 — intervention group
Group type: COMPARATOR
Intervention: DHEAS
Number of subjects: 16
Study 15780531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 16
Study 12413000 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 2 sessions of 10 minutes of training at 30% of PImax, daily for 4 weeks
Number of subjects: 12
Study 12413000 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Stretch Gymnastics (RMSG) - 3 sessions of 5 RMSG patterns 4 times each, daily for 4 weeks
Number of subjects: 12
Study 12413000 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RMSG and IMT
Number of subjects: 12
Study 10530772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg orally, twice daily
Number of subjects: 64
Study 10530772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7839300 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 0
Study 7839300 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 7839300 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 1746970 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU administration (300-600 mg/day x 12 weeks or more)
Number of subjects: 191
Study 1746970 — intervention group
Group type: COMPARATOR
Intervention: Radical therapy only (Control Group A)
Number of subjects: 191
Study 6180562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (400 mg daily)
Number of subjects: 12
Study 6180562 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg daily)
Number of subjects: 12
Study 6180562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily)
Number of subjects: 12
Study 6180562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30566416 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Methylfolate (15 mg)
Number of subjects: 44
Study 30566416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28892431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed and cisplatin
Number of subjects: 87
Study 28892431 — intervention group
Group type: COMPARATOR
Intervention: Nintedanib
Number of subjects: 87
Study 26197360 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative spoken words
Number of subjects: 0
Study 26197360 — intervention group
Group type: EXPERIMENTAL
Intervention: Taboo spoken words
Number of subjects: 0
Study 26197360 — intervention group
Group type: EXPERIMENTAL
Intervention: First block of trials with emotional words
Number of subjects: 0
Study 24473908 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) with targeted biopsies
Number of subjects: 168
Study 24473908 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE) with standard biopsy protocol
Number of subjects: 168
Study 21761215 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19442311 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline incision with continuous fascial closure using slowly absorbable sutures (n=47, 55%) and braided sutures (n=32, 38%) with strength of 1 (n=48, 57%).
Number of subjects: 157
Study 19442311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision with continuous fascial closure using slowly absorbable sutures (n=22, 41%) and braided sutures (n=27, 50%) with strength of 1 (n=30, 56%).
Number of subjects: 157
Study 15202624 — intervention group
Group type: EXPERIMENTAL
Intervention: Home cooking group
Number of subjects: 44
Study 15202624 — intervention group
Group type: COMPARATOR
Intervention: Clinic cooking group
Number of subjects: 44
Study 15202624 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 44
Study 11316402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11316402 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 100
Study 11316402 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 100
Study 11316402 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 4 mg
Number of subjects: 100
Study 9666879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg orally once daily for 12 months)
Number of subjects: 39
Study 9666879 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200-600 mg orally daily)
Number of subjects: 39
Study 9666879 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 39
Study 9666879 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole alone
Number of subjects: 39
Study 9666879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate and ketoconazole
Number of subjects: 39
Study 9666879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 39
Study 7978133 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte 148
Number of subjects: 30
Study 7978133 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 30
Study 31325468 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic direct-acting antivirals (DAAs) with sofosbuvir + ledipasvir ± ribavirin or sofosbuvir + daclatasvir ± ribavirin
Number of subjects: 48088
Study 31325468 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic direct-acting antivirals (DAAs)
Number of subjects: 48088
Study 27672000 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-PLIF
Number of subjects: 78
Study 27672000 — intervention group
Group type: COMPARATOR
Intervention: Freehand-PLIF
Number of subjects: 78
Study 25952121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manual acupuncture and massage therapy (MAMT)
Number of subjects: 96
Study 25952121 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture therapy (MAT)
Number of subjects: 96
Study 24364801 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) treatment for depression
Number of subjects: 23
Study 21515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy plus either switch to another selective serotonin reuptake inhibitor (SSRI) or switch to venlafaxine
Number of subjects: 190
Study 21515198 — intervention group
Group type: COMPARATOR
Intervention: Switch to another selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 190
Study 21515198 — intervention group
Group type: COMPARATOR
Intervention: Switch to venlafaxine
Number of subjects: 190
Study 18638603 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment using tissue Doppler imaging
Number of subjects: 74
Study 18638603 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic assessment using pulse-wave Doppler
Number of subjects: 74
Study 16522426 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat corticosteroids
Number of subjects: 0
Study 16522426 — intervention group
Group type: COMPARATOR
Intervention: Single course corticosteroids
Number of subjects: 0
Study 14579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabesk and Solobond
Number of subjects: 36
Study 14579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Z 100 and Scotchbond 1
Number of subjects: 36
Study 14579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigy and OptiBond
Number of subjects: 36
Study 14579884 — intervention group
Group type: EXPERIMENTAL
Intervention: FHC Merz light and Resulcin Aqua Prime/Monobond
Number of subjects: 36
Study 14579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sculpt‐It and Bond 1
Number of subjects: 36
Study 14579884 — intervention group
Group type: COMPARATOR
Intervention: Amelogen Universal with Permaquick (control)
Number of subjects: 36
Study 14579884 — intervention group
Group type: COMPARATOR
Intervention: Enamel versus human enamel (control for wear rates)
Number of subjects: 36
Study 11049707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose gentamicin (4.5 mg/kg) plus metronidazole (500 mg) preoperatively
Number of subjects: 146
Study 11049707 — intervention group
Group type: COMPARATOR
Intervention: Multiple standard dose gentamicin (1.5 mg/kg) plus metronidazole (500 mg) preoperatively and every 8h for 24h postoperatively
Number of subjects: 146
Study 8776678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.72 g/kg (0.9 ml/kg) of ethanol
Number of subjects: 40
Study 8776678 — intervention group
Group type: COMPARATOR
Intervention: Control group (family history negative controls matched on demography and substance use histories)
Number of subjects: 40
Study 1458013 — intervention group
Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 70
Study 1458013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GH plus oxandrolone
Number of subjects: 70
Study 1458013 — intervention group
Group type: COMPARATOR
Intervention: GH alone and combination therapy
Number of subjects: 70
Study 1458013 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 70
Study 3881209 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg bolus followed by 5 micrograms h‐1 kg‐1 infusion)
Number of subjects: 9
Study 3881209 — intervention group
Group type: COMPARATOR
Intervention: Saline (corresponding volume bolus followed by saline infusion)
Number of subjects: 9
Study 31101977 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient supplementation (omega‐3 fatty acids, folic acid, selenium, vitamin E, catechin, glycyrrhizin, and co‐enzyme Q10) for 3 months
Number of subjects: 60
Study 31101977 — intervention group
Group type: COMPARATOR
Intervention: Control group (two unlabeled soft capsules containing 200 μg folic acid each, for 3 months)
Number of subjects: 60
Study 28492084 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measurement
Number of subjects: 711
Study 28492084 — intervention group
Group type: COMPARATOR
Intervention: Routine work-up
Number of subjects: 711
Study 27082551 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 4299
Study 27082551 — intervention group
Group type: COMPARATOR
Intervention: Baseline heart rate (highest vs lowest quartile)
Number of subjects: 4299
Study 27082551 — intervention group
Group type: COMPARATOR
Intervention: Last assessment heart rate
Number of subjects: 4299
Study 27082551 — intervention group
Group type: COMPARATOR
Intervention: Mean heart rate
Number of subjects: 4299
Study 27082551 — intervention group
Group type: COMPARATOR
Intervention: Baseline heart rate adjusted for mean systolic blood pressure
Number of subjects: 4299
Study 27082551 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 4299
Study 24909468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg and Metoclopramide 10 mg (DM group)
Number of subjects: 90
Study 24909468 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg (MO group)
Number of subjects: 90
Study 24909468 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg (DO group)
Number of subjects: 90
Study 22286528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-protein diet (30% protein, 40% carbohydrate, 30% fat)
Number of subjects: 419
Study 22286528 — intervention group
Group type: COMPARATOR
Intervention: Low-fat high-carbohydrate diet (15% protein, 55% carbohydrate, 30% fat)
Number of subjects: 419
Study 22286528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low-fat high-protein and low-fat high-carbohydrate)
Number of subjects: 419
Study 20157135 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Number of subjects: 16608
Study 17343543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol, 50 microg every 4 h for up to three doses
Number of subjects: 130
Study 17343543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 130
Study 17343543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 15525998 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 62
Study 15525998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11986955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) treatment
Number of subjects: 38
Study 11986955 — intervention group
Group type: COMPARATOR
Intervention: Control (without CsA)
Number of subjects: 38
Study 9673558 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44 variant 6 positive
Number of subjects: 98
Study 9673558 — intervention group
Group type: COMPARATOR
Intervention: CD44 variant 6 negative and lymphatic invasion negative
Number of subjects: 98
Study 8087629 — intervention group
Group type: EXPERIMENTAL
Intervention: HME filters (Hygrobaby DAR)
Number of subjects: 28
Study 8087629 — intervention group
Group type: COMPARATOR
Intervention: Traditional humidifiers (Bennett Cascade Humidifier)
Number of subjects: 28
Study 2667758 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg bid for 2 days
Number of subjects: 9
Study 335924 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (170 micrograms)
Number of subjects: 24
Study 335924 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (150 micrograms)
Number of subjects: 24
Study 335924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30654643 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 152
Study 30654643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 30654643 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine and Placebo
Number of subjects: 152
Study 27077785 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation and amniotic membrane graft (AMG)
Number of subjects: 40
Study 27077785 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG) with tissue debridement
Number of subjects: 40
Study 25487027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free sodium hyaluronate 0.1% and preservative-free fluorometholone 0.1% eyedrops, 4 times a day in the first month and twice a day in the second month.
Number of subjects: 80
Study 25487027 — intervention group
Group type: COMPARATOR
Intervention: Preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops, 4 times a day in the first month and twice a day in the second month.
Number of subjects: 80
Study 24070809 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF inhibition (anti-VEGF therapy)
Number of subjects: 509
Study 21651869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia
Number of subjects: 90
Study 21651869 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane inhalation anesthesia
Number of subjects: 90
Study 18728936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme in a Mediterranean climate
Number of subjects: 124
Study 18728936 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation programme in a Norwegian climate
Number of subjects: 124
Study 16772718 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTO regimen (4 years alternating treatment and observation, n = 30)
Number of subjects: 58
Study 16772718 — intervention group
Group type: EXPERIMENTAL
Intervention: TTOO regimen (2 years treatment followed by 2 years observation, n = 28)
Number of subjects: 58
Study 16772718 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TOTO and TTOO)
Number of subjects: 58
Study 16772718 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTO regimen
Number of subjects: 58
Study 16772718 — intervention group
Group type: EXPERIMENTAL
Intervention: TTOO regimen
Number of subjects: 58
Study 15115951 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide
Number of subjects: 2600
Study 11198661 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. vaccine
Number of subjects: 296
Study 11198661 — intervention group
Group type: COMPARATOR
Intervention: i.m. placebo
Number of subjects: 296
Study 9056064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (375 mg)
Number of subjects: 10
Study 9056064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 8116453 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 100 mg of bisaramil
Number of subjects: 6
Study 8116453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of 35 mg of bisaramil
Number of subjects: 6
Study 3086575 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (40 mg)
Number of subjects: 40
Study 3086575 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa (60 mg)
Number of subjects: 40
Study 30250134 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 122
Study 30250134 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Aerobic Training (Diet + AT)
Number of subjects: 122
Study 30250134 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Resistance Training (Diet + RT)
Number of subjects: 122
Study 29360529 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181
Study 29360529 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostate resection
Number of subjects: 181
Study 26014280 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for confrontation when sexism is perceived as rare
Number of subjects: 552
Study 26014280 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for confrontation when sexism is perceived as pervasive
Number of subjects: 552
Study 26014280 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal self-affirmation manipulation
Number of subjects: 552
Study 22180582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine (1.0 mcg/kg/min)
Number of subjects: 3
Study 22180582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (targeted breathalyzer of 40 mg% and 80 mg%)
Number of subjects: 3
Study 22180582 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine
Number of subjects: 3
Study 22180582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 3
Study 19878041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic agents (citrate buffer solution, pineapple juice, green mango juice)
Number of subjects: 35
Study 19878041 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% acetic acid at 80 degrees C
Number of subjects: 35
Study 19878041 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 35
Study 19878041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic agents
Number of subjects: 35
Study 17712585 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml orange juice and 250 ml blackcurrant juice
Number of subjects: 48
Study 17712585 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg vitamin E
Number of subjects: 48
Study 17712585 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml orange juice and 250 ml blackcurrant juice and 15 mg vitamin E
Number of subjects: 48
Study 17712585 — intervention group
Group type: COMPARATOR
Intervention: Control/placebo (energy-equivalent sugar-containing beverage)
Number of subjects: 48
Study 16228828 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 391
Study 16228828 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 391
Study 12171815 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 0.35
Number of subjects: 13
Study 12171815 — intervention group
Group type: COMPARATOR
Intervention: FIO2 of 0.21 (control)
Number of subjects: 13
Study 10464824 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 0.4 mg kg‐1
Number of subjects: 0
Study 10464824 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 10464824 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate and midazolam sedation
Number of subjects: 0
Study 8541826 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Rehabilitation Group (ARG)
Number of subjects: 40
Study 8541826 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 2702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg nocte) - Long-term treatment
Number of subjects: 60
Study 2702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg nocte) - Seasonal treatment
Number of subjects: 60
Study 2702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg nocte) - Multicenter trial
Number of subjects: 60
Study 319922 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine
Number of subjects: 108
Study 319922 — intervention group
Group type: EXPERIMENTAL
Intervention: bethanidine
Number of subjects: 108
Study 30955307 — intervention group
Group type: EXPERIMENTAL
Intervention: CSVD group (199 patients)
Number of subjects: 199
Study 30955307 — intervention group
Group type: EXPERIMENTAL
Intervention: CSVD-VCI group (112 patients)
Number of subjects: 199
Study 30955307 — intervention group
Group type: EXPERIMENTAL
Intervention: Declined LVEF
Number of subjects: 199
Study 30955307 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (NC group, 103 healthy elderly persons)
Number of subjects: 199
Study 27483410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 550
Study 27483410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) + etanercept (ETN) combination therapy
Number of subjects: 550